Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sientra (NASDAQ: SIEN) and Inovio Pharmaceuticals (NASDAQ: INO) with bullish sentiments.

Sientra (NASDAQ: SIEN)

In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sientra (NASDAQ: SIEN), with a price target of $19. The company’s shares closed yesterday at $16.71, close to its 52-week high of $17.28.

Vendetti observed:

“1Q18 total net revenue of $14.7M, up 96.0% y/y as-reported and up 29.8% y/y pro forma, was slightly above the preannouncement of $14.5M. This includes breast products revenue of $8.5M, up 14% y/y, and miraDry revenue of $6.1M, up 61% y/y pro forma. A GAAP loss of ($0.99) per share, compared to ($0.61) in 1Q17, was wider than both our estimate of ($0.81) and consensus of ($0.88). On the company closed a public offering for 8,518,519 shares of common stock priced at $13.50 per share for net proceeds of $107.7M..”

Vendetti has an average return of 50.7% when recommending Sientra.

According to TipRanks.com, Vendetti is ranked #570 out of 4793 analysts.

Sientra has an analyst consensus of Strong Buy, with a price target consensus of $17.

See today’s analyst top recommended stocks >>

Inovio Pharmaceuticals (NASDAQ: INO)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO) today and set a price target of $8. The company’s shares closed yesterday at $4.83.

McCarthy said:

“Inovio reported 1Q18 with revenue of $1.5M (grants, collaborations) and a net loss of $32.4M. The company ended the period with $112M in cash..”

According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.3% and a 37.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Currently, the analyst consensus on Inovio Pharmaceuticals is Strong Buy and the average price target is $11.67, representing a 141.6% upside.

In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $13 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.